Poolbeg Pharma PLC
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Poolbeg Pharma PLC (AIM: POLB), a clinical-stage biopharmaceutical company headquartered in London and founded in 2021, develops innovative medicines targeting unmet needs in infectious diseases, cancer immunotherapy and metabolic disorders. The company employs a capital-light model leveraging artificial intelligence and human challenge trial data for faster, cost-effective drug discovery and advancement. Poolbeg Pharma operates primarily in the United Kingdom with a global development focus and maintains a pipeline including POLB 001, an oral p38 MAPK inhibitor to prevent cytokine release syndrome associated with cancer immunotherapies such as CAR-T and bispecific antibodies; POLB 001 for severe influenza; an oral encapsulated GLP-1R agonist for obesity, diabetes and other metabolic conditions using a generally regarded as safe delivery system; AI-driven novel discovery programmes for influenza and respiratory syncytial virus; POLB 002, an in-licensed first-in-class broad-spectrum RNA-based intra-nasal immunotherapy for respiratory virus infections including influenza, RSV and SARS-CoV-2; and POLB 003, an intramuscular vaccine candidate for melioidosis prevention. Recent developments include securing orphan drug designation from the FDA for POLB 001 as a preventative therapy for T-cell engager bispecific antibody-induced cytokine release syndrome; positive in vivo data supporting POLB 001's efficacy against bispecific antibody-induced cytokine release syndrome; free supply of an approved bispecific antibody from a major pharmaceutical partner for the ongoing Phase 2a trial at The Christie hospital; a successful oversubscribed fundraising of £4.865 million in May 2025 extending cash runway into 2027 to fund POLB 001 Phase 2a and oral GLP-1 proof-of-concept trials; and preparations for multiple clinical milestones in 2026 across oncology and obesity programmes.
Poolbeg wins Israeli patent nod for lead cancer immunotherapy drug
Poolbeg Pharma raises £3.5m to support key trial and GLP-1 progress
Cavendish sees multi-billion-dollar prize as Poolbeg begins pivotal trial
Poolbeg doses first patient in cancer immunotherapy safety trial
Poolbeg Pharma secures South African patent for lead drug candidate
Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish
European patent boosts Poolbeg Pharma's POLB 001 IP portfolio
Poolbeg Pharma has begun an exciting new clinical trial - ICYMI
Poolbeg Pharma shows clinical progress with latest updates
Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners
Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners
Poolbeg Pharma gets positive FDA feedback for development pathway of lead cancer therapy asset
Poolbeg Pharma secures Canadian patent for cancer immunotherapy drug POLB 001
Poolbeg Pharma PLC (POLBF) Q4 2025 Earnings Call Transcript
Poolbeg eyes transformative summer with POLB 001 data in prospect
FTSE 100 Live: BP and Shell provide boost as oil hits $110, Barclays falls on results
Poolbeg Pharma eyes partnering deals as cancer immunotherapy trial heads for summer data
FTSE 100 Live: London blue-chips led lower by miners, builders and airlines
Poolbeg Pharma advances POLB 001 into UK trial - ICYMI
Poolbeg Pharma advances POLB 001 into UK trial - ICYMI